✓ No active regulatory warningsFDA MedWatch, EMA EudraVigilance, WHO VigiBase, WADA Prohibited List · 2026-05-29
📰Read the full Omega-3 EPA evidence review on GMJ News →Complete clinical article, references and updates on news.gmj.ge. This page is the structured safety summary.⚠ REDUCE-IT: 25% CV event reduction with pure EPA (NNT=21) [2]
⚠ STRENGTH (EPA+DHA) was negative — pure EPA may be superior [2]
⚠ Depression: EPA-predominant (≥60%) formulations only [1]
⚠ Antiplatelet at >3 g/day [1]
ℹ️ Not obtained from food. Not applicable — this is not obtained from food in meaningful amounts; supplementation is the practical route.
🔬 Lab interpreter
Recommended test
Triglycerides, lipid panel
Triglycerides, lipid panel
Reference range / target
TG reduction 20–45%
TG reduction 20–45%
REDUCE-IT criteria: TG 150–499 on statin [2].
Full lab monitoring ↓⚕ For professionals — confirm ranges against your local laboratory.
Clinical verdict
EPA is the anti-inflammatory omega-3. REDUCE-IT: pure EPA 4 g/day (Vascepa) reduced CV events 25% — the most important supplement-to-drug trial ever. EPA-predominant for depression (meta-analyses favor ≥60% EPA). STRENGTH trial (EPA+DHA) was negative — EPA alone may be the key. See Fish Oil entry for comprehensive data [1] [2].
1 How much do I need?
👤 Adults: Specific dosage data under clinical review
👴 Elderly: Specific dosage data under clinical review
🤰 Pregnancy: See guidance
DHA prioritized for brain. EPA + DHA both recommended [1].
👦 Pediatric: See guidance
See Fish Oil entry [1].
🏃 Athletes: Standard dose
⚖️ Obesity: Standard dose
Fat-soluble compounds may require dose adjustment in obesity.
🩺 Renal: Consult specialist
Dose adjustment may be needed in renal impairment.
🌱 Vegan: Standard dose
How to take
🍽 Timing: With fat-containing meal [1].
💊 With food: With fat [1].
🚫 Avoid: See Fish Oil entry [1].
2 Which form?
| Form | Bioavailability | Vegan | Cost |
|---|---|---|---|
| ['Vascepa/icosapent ethyl (Rx)', 'preferred', 'Pure EPA ethyl ester. 4 g/day. FDA-approved CV indication [2].'] | Standard | Check label | |
| ['EPA-concentrated fish oil', 'common', 'OTC. Various EPA concentrations [1].'] | Standard | Check label | |
| ['Algae EPA', '', 'Newer algae strains produce EPA (not just DHA) [1].'] | Standard | Check label |
3 Common questions
Why did REDUCE-IT use pure EPA, not fish oil? ▼
REDUCE-IT specifically tested pure EPA (no DHA). The STRENGTH trial (EPA+DHA) was negative for CV outcomes. This suggests EPA's anti-inflammatory mechanism is specific and DHA may have diluted the benefit in mixed formulations. The debate continues [2].
EPA vs DHA for depression? ▼
Meta-analyses consistently favor EPA-predominant formulations (≥60% EPA). DHA-predominant formulations are not significantly better than placebo for depression. The mechanism may involve EPA's effects on neuroinflammation [1].
4 Clinical evidence
Strong
REDUCE-IT (n=8,179): pure EPA 4 g/day reduced MACE by 25% in statin-treated patients with TG 150–499. NNT=21 [2]. EPA competes with arachidonic acid for COX/LOX: established eicosanoid pharmacology [1]. HIGH
Moderate
Depression: meta-analyses favor EPA-predominant formulations over DHA-predominant or placebo [1]. Triglycerides: EPA 2–4 g/day reduces TG 20–45% [1]. Anti-inflammatory: reduced CRP and inflammatory markers [1]. MODERATE
Insufficient
5 Safety, toxicity & adverse events
Absolute contraindications
✕ Fish/seafood allergy (fish-derived products)
Relative
⚠ High doses with anticoagulants/antiplatelets — bleeding risk
⚠ Discontinue high doses before surgery
⚠ Atrial fibrillation — a dose-related signal at high intake is under study
🚩 Red flags
● AFib history — REDUCE-IT showed increased AFib with high-dose EPA [2]
● Anticoagulant + high-dose EPA — bleeding [1]
6 Interactions
Drug interactions
Anticoagulants Moderate
Mechanism: EPA antiplatelet effects at >3 g/day. [1]
Effect: Bleeding risk. [1]
Action: Monitor [1].
Supplement synergies
Statin (for REDUCE-IT benefit) · Per cardiology
REDUCE-IT: Vascepa added to statin therapy [2].
REDUCE-IT: Vascepa added to statin therapy [2].
7 Regulatory
United States (FDA): Vascepa (icosapent ethyl): FDA-approved to reduce CV risk in statin-treated patients with elevated TG (2019). Landmark supplement-to-drug transition [2].
8 US supplement products
1
on-market products containing Omega-3 EPA (NIH DSLD)
Brands carrying Omega-3 EPA (1)
Click a brand to see its Omega-3 EPA products.
9 Frequently paired with
10 Cite this page
Vancouver: Pkhakadze G. Omega-3 EPA — safety profile [Internet]. Tbilisi: PHIG; 2026 [cited 2026 Aug 07]. Available from: https://supplement.ge/ingredients/omega-3-epa/
APA 7th: Pkhakadze, G. (2026). Omega-3 EPA — Safety profile. Public Health Institute of Georgia. https://supplement.ge/ingredients/omega-3-epa/
📋 Editorial information
Author: Prof. G. Pkhakadze, MD, MPH, PhD
Institution: Public Health Institute of Georgia (PHIG)
Affiliation: David Tvildiani Medical University (DTMU)
First published: January 2026
Last reviewed: 2026-05-29
Next review: February 2027
References: 4 cited sources
COI: SupplementIndex receives no funding from supplement manufacturers. All content independently authored by PHIG.
Process: Systematic literature review
📄 License & reuse
Published under Creative Commons Attribution 4.0 International (CC BY 4.0). You may share and adapt for any purpose with attribution.
Pkhakadze G. "Omega-3 EPA — Safety Profile." SupplementIndex, PHIG, 2026. https://supplement.ge/ingredients/omega-3-epa/ CC BY 4.0.
GP
Prof. G. Pkhakadze, MD, MPH, PhD
Professor of Public Health · Head of Department, DTMU
Editor-in-Chief, Georgian Medical Journal (ISSN 3088-4322)
Chair, Public Health Institute of Georgia · UEMS Public Health Section
Educational and public health purposes. CC BY 4.0. Consult your healthcare provider before starting any supplement. Corrections: info@accreditation.ge. Publisher: PHIG